WO2023134787A3 - 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 - Google Patents
抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 Download PDFInfo
- Publication number
- WO2023134787A3 WO2023134787A3 PCT/CN2023/081308 CN2023081308W WO2023134787A3 WO 2023134787 A3 WO2023134787 A3 WO 2023134787A3 CN 2023081308 W CN2023081308 W CN 2023081308W WO 2023134787 A3 WO2023134787 A3 WO 2023134787A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- hepatocellular carcinoma
- combination
- treatment
- Prior art date
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了抗PD-1抗体或其抗原结合片段与抗VEGF抗体或其抗原结合片段的药物组合，以及其在制备治疗肝细胞癌的药物中的用途；其中，所述抗PD-1抗体或其抗原结合片段包含氨基酸序列如SEQ ID NO：1、SEQ ID NO：2和SEQ ID NO：3所示的LCDR1、LCDR2和LCDR3，和氨基酸序列如SEQ ID NO：4、SEQ ID NO：5和SEQ ID NO：6所示的HCDR1、HCDR2和HCDR3。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202380017146.4A CN118613280A (zh) | 2022-01-14 | 2023-03-14 | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210042847.0 | 2022-01-14 | ||
| CN202210042847 | 2022-01-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023134787A2 WO2023134787A2 (zh) | 2023-07-20 |
| WO2023134787A3 true WO2023134787A3 (zh) | 2023-09-07 |
Family
ID=87280138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/081308 WO2023134787A2 (zh) | 2022-01-14 | 2023-03-14 | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN118613280A (zh) |
| WO (1) | WO2023134787A2 (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170166641A1 (en) * | 2014-02-04 | 2017-06-15 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| CN108348575A (zh) * | 2015-09-01 | 2018-07-31 | 日东制药株式会社 | 用于预防和治疗癌症或血管生成相关疾病的药物组合物，其含有作为有效成分的融合蛋白，该融合蛋白融合了肿瘤穿透肽和抗血管生成剂 |
| CN110882385A (zh) * | 2018-09-07 | 2020-03-17 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| WO2021228069A1 (zh) * | 2020-05-12 | 2021-11-18 | 信达生物制药(苏州)有限公司 | 抗vegf抗体和抗pd-1抗体组合用于预防或治疗疾病的应用 |
-
2023
- 2023-03-14 WO PCT/CN2023/081308 patent/WO2023134787A2/zh unknown
- 2023-03-14 CN CN202380017146.4A patent/CN118613280A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170166641A1 (en) * | 2014-02-04 | 2017-06-15 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| CN108348575A (zh) * | 2015-09-01 | 2018-07-31 | 日东制药株式会社 | 用于预防和治疗癌症或血管生成相关疾病的药物组合物，其含有作为有效成分的融合蛋白，该融合蛋白融合了肿瘤穿透肽和抗血管生成剂 |
| CN110882385A (zh) * | 2018-09-07 | 2020-03-17 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| WO2021228069A1 (zh) * | 2020-05-12 | 2021-11-18 | 信达生物制药(苏州)有限公司 | 抗vegf抗体和抗pd-1抗体组合用于预防或治疗疾病的应用 |
Non-Patent Citations (1)
| Title |
|---|
| KUDO MASATOSHI: "Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma", CANCERS, vol. 12, no. 5, 1 January 2020 (2020-01-01), pages 1089, XP093081142, DOI: 10.3390/cancers12051089 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118613280A (zh) | 2024-09-06 |
| WO2023134787A2 (zh) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| RS53157B (en) | SCLEROSTINE ANTIBODIES | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ595011A (en) | Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases | |
| NZ714313A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| NZ600512A (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| NZ592436A (en) | Treatment with anti-alpha2 integrin antibodies | |
| NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| JP2013542194A5 (zh) | ||
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| NZ610153A (en) | Novel anti-dr5 antibody | |
| HRP20200882T1 (hr) | Vezujuće molekule specifične za asct2 i njihova uporaba | |
| JP2023055904A5 (zh) | ||
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| ZA202211457B (en) | Anti-cd73 antibody and use thereof | |
| JP2024024114A5 (zh) | ||
| JP2019512472A5 (zh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23740127 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |